Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1997-04-08
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514557, 514570, 514684, 514690, 514717, 514719, A61K 31335, A61K 3119, A61K 3112, A61K 31075
Patent
active
056188374
ABSTRACT:
Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an effective amount of Brefeldin A or a derivative of Brefeldin A. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The non-peptide PDGF antagonists Brefeldin A and its derivatives may optionally be administered coordinately with heparin, whereby the coordinately administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia.
REFERENCES:
patent: 5250519 (1993-10-01), Conrad et al.
Ostman et al., J. Cell Biol. 118: 509-519, 1992.
Kimura et al., Japan. J. Pharmacol. 59: 51-56, 1992.
Castellot et al., J. Cell. Biol. 109(6): 3147-3155, 1989.
Cavari et al., Cell Biol. Intl. 17(8): 781-786, 1993.
Reilly et al., J. Cell. Phys. 136: 23-32, 1988.
Guyton et al., Circulation Research 46(5): 625-634, 1980.
Popma et al., Circulation 84(3): 1426-1436, 1991.
Ferrell et al., Circulation 85(4): 1630-1631, 1992.
Lindner et al., J. Clin. Invest. 90: 2044-2049, 1992.
Jawien et al., J. Clin. Invest. 89: 507-511, 1992.
Lindner et al., J. Clin. Invest. 85: 2004-2008, 1990.
Currier et al., JACC 17: 118B-125B, 1991.
Schmid et al., Seminars in Thrombosis and Hemostasis 19, Suppl. 1: 155-159, 1993.
Edelman et al., Proc. Natl. Acad. Sci. USA 87: 3773-3777, 1990.
Rubin et al., Lancet Jun. 18, 1988: 1353-1356, 1988.
Buchwald et al., Circulation 86(2): 531-537, 1992.
Hart Charles E.
Martinez Theresa
McConnell Oliver J.
West Robert R.
Jordan Kimberly
Leith Debra K.
Parker Gary E.
Sawislak Deborah A.
ZymoGenetics Inc.
LandOfFree
PDGF antagonists III does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PDGF antagonists III, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PDGF antagonists III will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2398095